• 1
    National Asthma Education and Prevention Program (NAEPP). Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute. Bethesda, MD: National Institutes of Health, 1997.
  • 2
    National Asthma Education Prevention Program (NAEPP). Expert Panel Report: guidelines for the diagnosis and management of asthma – update on selected topics. J Allergy Clin Immunol 2002; 110: S141219.
  • 3
    Pauwels R. Use of corticosteroids in asthma. In: Pharmacy and Pharmacotherapy of Asthma, eds D'ArcyPF, McElnayJL. Chichester: Ellis Harwood, 1989: 10418.
  • 4
    Edsbäcker S. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 1999; 58 (Suppl. 4): 716.
  • 5
    Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157: S1S53.
  • 6
    Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44: 375407.
  • 7
    Campbell LM, Watson DG, Venables TL, Taylor MD, Richardson PDL. Once daily budesonide Turbohaler compared with placebo as initial prophylactic therapy for asthma. Br J Clin Res 1991; 2: 11122.
  • 8
    Jones AH, Langdon CG, Lee PS, Lingham SA, Nankani JP, Follows RM, Tollemar U, Richardson PD. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Respir Med 1994; 88: 2939.
  • 9
    Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide: novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26: 62330.
  • 10
    Thorsson L, Edsbäcker S, Källén A, Löfdahl CG. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001; 52: 52938.
  • 11
    Tunek A, Sjödin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997; 11: 13117.
  • 12
    Wieslander E, Delander E-L, Sjödin K, Tunek A, Brattsand R. Fatty acid conjugation in normal human bronchial epithelial cells. Am J Respir Crit Care Med 1998; 157: A402.
  • 13
    Purucker ME, Rosebraugh CJ, Zhou F, Meyer RJ. Inhaled fluticasone propionate by Diskus in the treatment of asthma: a comparison of the efficacy and safety of the same nominal dose given either once or twice a day. Chest 2003; 124: 158493.
  • 14
    Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 2005; 18: 3906.
  • 15
    Van den Bosch JM, Westermann CJ, Aumann J, Edsbäcker S, Tonnesson M, Selroos O. Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos 1993; 14: 4559.
  • 16
    Esmailpour N, Högger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997; 10: 14969.
  • 17
    Jendbro M, Johansson J-M, Strandberg P, Falk-Nilsson H, Edsbäcker S. Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. Drug Metab Dispos 2001; 29: 76976.
  • 18
    Thorsson L, Thunnisen FBJM, Korn S, Carlshaf A, Edsbäcker S, Wouters EFM. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo. Am J Respir Crit Care Med 1998; 157: A404.
  • 19
    Davies NM, Feddah MIR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharmaceut 2003; 255: 17587.
  • 20
    Edsbäcker S, Brattsand R. Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol 2002; 88: 60916.
  • 21
    Petersen H, Kullberg A, Edsbäcker S, Greiff L. Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo. Br J Clin Pharmacol 2001; 51: 15963.
  • 22
    Drollmann A, Watz H, Nave R, Boss H, Magnussen H, Hoffmann H. In vivo metabolism of ciclesonide in the human lung. Proc Am Tnorac Soc 2006; 3 (Suppl. 3): A75.
  • 23
    Dahlberg E, Thalén A, Brattsand R, Gustafsson J-Å, Johansson U, Roempke K, Saartok T. Correlation between chemical structure, receptor binding and biological activity of some novel, highly active 16α, 17α-acetal substituted glucocorticoids. Mol Pharmacol 1984; 25: 706.
  • 24
    Wieslander E, Delander E-L, Järkelid L, Hjertberg E, Tunek A, Brattsand R. Pharmacologic importance of the reversible fatty acid conjugation of budesonide studies in a rat cell line in vitro. Am J Respir Cell Mol Biol 1998; 19: 47784.
  • 25
    Selroos O, Edsbäcker S, Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. J Asthma 2004; 41: 77190.